InspireMD, Inc.
InspireMD, Inc.（NSPR）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · NSPR · 截至 2025年9月30日
股东结构概览
41
机构持有人数
▲ 5 vs Q2
$54.78M
机构持仓总市值
▲ $22.86M vs Q2
46.84M
总流通股
freeFloat 56.14%
22.73M
13F 申报持股数
▲ 8.67M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
NSPR 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
ROSALIND ADVISORS, INC. surgical & medical instruments & apparatus | 3.91M | 7.66% | 7.66% | $9.41B | Nov 13, 2025 | ▲ 1.62M |
NANTAHALA CAPITAL MANAGEMENT, LLC surgical & medical instruments & apparatus | 3.38M | 6.62% | 6.62% | $8.14B | Nov 14, 2025 | ▲ 1.06M |
ABRDN PLC surgical & medical instruments & apparatus | 2.48M | 4.86% | 4.86% | $5.98B | Nov 7, 2025 | NEW |
PARKMAN HEALTHCARE PARTNERS LLC surgical & medical instruments & apparatus | 2.44M | 4.79% | 4.79% | $5.88B | Nov 14, 2025 | ▲ 1.21M |
VELAN CAPITAL INVESTMENT MANAGEMENT LP surgical & medical instruments & apparatus | 2.14M | 4.20% | 4.20% | $5.17B | Nov 14, 2025 | ▲ 1.24M |
ORBIMED ADVISORS LLC surgical & medical instruments & apparatus | 2.13M | 4.18% | 4.18% | $5.14B | Nov 14, 2025 | — held |
MARSHALL WACE, LLP surgical & medical instruments & apparatus | 1.86M | 3.65% | 3.65% | $4.48B | Nov 13, 2025 | — held |
SOLEUS CAPITAL MANAGEMENT, L.P. surgical & medical instruments & apparatus | 1.47M | 2.88% | 2.88% | $3.54B | Nov 14, 2025 | ▼ 415.3K |
GHISALLO CAPITAL MANAGEMENT LLC surgical & medical instruments & apparatus | 921.6K | 1.81% | 1.81% | $2.22B | Nov 14, 2025 | NEW |
PURA VIDA INVESTMENTS, LLC surgical & medical instruments & apparatus | 450.5K | 88.33% | 88.33% | $1.09B | Nov 12, 2025 | — held |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
16
增持
+5.60M 股9
新建仓
首次建仓3
减持
−435.2K 股5
清仓
完全退出净股数变化（前50家）
+5.17M
+5.60M / −435.2K
净新增持仓人
+17
新建 9 个 / 退出 5 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
NSPR 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
11
买入笔数
1
卖出笔数
11.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Stuka Paul director | May 27, 2026 | Purchase | 20,000 | $0.88 | $17.5K | 667.9K | Form 4 ↗ |
Gleason Shane Thomas Chief Commercial Officer | Jan 27, 2025 | Sale | 3,858 | $2.71 | $10.5K | 1.14M | Form 4 ↗ |
Gleason Shane Thomas Chief Commercial Officer | Jan 28, 2025 | Sale | 2,476 | $2.61 | $6.5K | 1.13M | Form 4 ↗ |
Gleason Shane Thomas Chief Commercial Officer | Jan 29, 2025 | Sale | 3,660 | $2.46 | $9.0K | 1.13M | Form 4 ↗ |
Gleason Shane Thomas Chief Commercial Officer | Jan 30, 2025 | Sale | 2,454 | $2.51 | $6.2K | 1.13M | Form 4 ↗ |
Gleason Shane Thomas Chief Commercial Officer | Jan 31, 2025 | Sale | 9,923 | $2.55 | $25.3K | 1.12M | Form 4 ↗ |
Gleason Shane Thomas Chief Commercial Officer | Feb 3, 2025 | Sale | 7,073 | $2.51 | $17.8K | 1.11M | Form 4 ↗ |
Gleason Shane Thomas Chief Commercial Officer | Feb 4, 2025 | Sale | 5,132 | $2.46 | $12.6K | 1.10M | Form 4 ↗ |
Gleason Shane Thomas Chief Commercial Officer | Feb 25, 2025 | Sale | 10,000 | $3.65 | $36.5K | 1.09M | Form 4 ↗ |
Gleason Shane Thomas Chief Commercial Officer | May 23, 2025 | Sale | 2,482 | $2.51 | $6.2K | 1.09M | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
InspireMD, Inc.（NSPR）主要由机构投资者持有，机构持股比例约为 48.5%。公司内部人员持股约 43.86%，散户及公众持股约占剩余的 7.61%。
InspireMD, Inc. 最大机构股东为 ROSALIND ADVISORS, INC.，截至 September 30, 2025 持有约 3.91 million 股，占总流通股的 7.66%。
目前共有 41 家机构持有 NSPR 股票，合计持仓市值约 $54,780,845，数据来源为最新 SEC 13F 申报。
常见问题
NSPR ownershipInspireMD, Inc.（NSPR）主要由机构投资者持有，机构持股约 48.5%。最大股东为 ROSALIND ADVISORS, INC.，持股比例 7.66%。内部人员持股约 43.86%。数据来源 SEC Form 13F，截至 September 30, 2025。